Tumor cell PD-L1 may mediate sensitivity to chemotherapy in colorectal cancer treatment

ROCHESTER, Minn. — Data in a study by Mayo Clinic Cancer Center researchers indicates that the level of tumor cell PD-L1, a protein that acts as a brake to keep the body's immune responses under control, may be an important factor for sensitivity to chemotherapy in colorectal cancer treatment. The study was published Friday, July 2, in Oncogene. "We have identified a mechanism by which absent or low levels of tumor cell PD-L1, which is commonly found…
Source: Mayo Clinic Research News - Category: Research Source Type: news